Startup | August 20, 2021
Caspian Debt to fund healthcare companies, partners Samridh
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
The company plans to invest in technology, business development, product innovation, and development across India
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Substantial reduction in losses
Subscribe To Our Newsletter & Stay Updated
